DAS181 Treatment of Severe Lower Respiratory Tract Parainfluenza Virus Infection in Immunocompromised Patients: A Phase 2 Randomized, Placebo-Controlled Study

BACKGROUND: There are no antiviral therapies for parainfluenza virus (PIV) infections. DAS181, a sialidase fusion protein, has demonstrated activity in in vitro and in animal models of PIV. METHODS: Adult immunocompromised patients diagnosed with PIV lower respiratory tract infection (LRTI) who requ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chemaly, Roy F, Marty, Francisco M, Wolfe, Cameron R, Lawrence, Steven J, Dadwal, Sanjeet, Soave, Rosemary, Farthing, Jason, Hawley, Stephen, Montanez, Paul, Hwang, Jimmy, Ho, Jennifer Hui-Chun, Lewis, Stanley, Wang, George, Boeckh, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326557/
https://www.ncbi.nlm.nih.gov/pubmed/33569576
http://dx.doi.org/10.1093/cid/ciab113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326557/
https://www.ncbi.nlm.nih.gov/pubmed/33569576
http://dx.doi.org/10.1093/cid/ciab113

Ejemplares similares